
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

December 17, 2018
Date of report (Date of earliest event reported)

GENPREX, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-38244
(Commission File Number)

90 - 0772347
(I.R.S. Employer
Identification Number)

**1601 Trinity Street,
Bldg B, Suite 3.322, Austin, TX**
(Address of principal executive offices)

78712
(Zip Code)

Registrant's telephone number, including area code: **(512) 537-7997**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors of Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Executive Officer Bonuses

On December 17, 2018, our Board of Directors, based on the recommendation of the Compensation Committee of the Board of Directors, approved cash bonus awards to our executive officers based on assessments of performance during 2018. The cash bonus amounts approved are as follows:

<u>Name</u>	<u>Title</u>	<u>Bonus Amount</u>
J. Rodney Vamer	Chief Executive Officer	\$165,375
Julien L. Pham, MD, MPH	President and Chief Operating Officer	\$125,205
Ryan M. Confer	Chief Financial Officer	\$120,000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GENPREX, INC.

Date: December 21, 2018

By: /s/ Ryan Confer
Ryan Confer
Chief Financial Officer
(Principal Financial Officer)